Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma

James K. Godfrey, Lei Gao, Geoffrey Shouse, Joo Y. Song, Stacy Pak, Brian Lee, Bihong T. Chen, Avyakta Kallam, John H. Baird, Guido Marcucci, Lucy Ghoda, Stephanie Vauleon, Alexey V. Danilov, Alex F. Herrera, Larry W. Kwak, Lihua E. Budde

Blood (2024) 144 (4): 457–461.

https://doi.org/10.1182/blood.2024024168

Published: 2024

Includes: Supplemental data

Journal Articles

A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

Blood (2022) 140 (Supplement 1): 9446–9447.

https://doi.org/10.1182/blood-2022-167173

Published: 2022

Journal Articles

Durable Leukemia and HIV Remission without Antiviral Therapy Following an Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) Using a Donor with CCR5-Δ32/Δ32 Homozygosity for an Acute Myeloid Leukemia (AML) Patient

Ahmed Aribi, Lihua E Budde, Joseph C. Alvarnas, Eileen P. Smith, Amandeep Salhotra, Monzr M. Al Malki, Wen Yi-Ping, John Zaia, Guido Marcucci, Jana Dickter, Stephen J Forman

Blood (2022) 140 (Supplement 1): 7597–7598.

https://doi.org/10.1182/blood-2022-169223

Published: 2022

Journal Articles

Physical Therapy Assessment of Baseline Function and Endurance Predicts Short Term Outcomes in Commercial CAR T Patients with Lymphoma

Geoffrey Shouse, Rachel Tran, Jesse Osborn, Lihua E Budde

Blood (2021) 138 (Supplement 1): 570.

https://doi.org/10.1182/blood-2021-150858

Published: 2021

Journal Articles

Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Alex F. Herrera, Jasmine Zain, Kerry J. Savage, Tatyana A. Feldman, Jonathan E Brammer, Lu Chen, Leslie L. Popplewell, Lihua E Budde, Matthew Mei, Lori A. Leslie, Ranjit Nair, Chitra Hosing, Lacolle Peters, Stephen J Forman, Steven T. Rosen, Larry W. Kwak, Swaminathan P Iyer

Blood (2021) 138 (Supplement 1): 133.

https://doi.org/10.1182/blood-2021-151105

Published: 2021

Journal Articles

Real World Evaluation of Deviation Outcomes in an Immune Effector Cell Quality Program

Geoffrey Shouse, DO, PhD, Sylvia O Dulan, RN, Jamie Wagner, BS, Michelle Mott, RN, Alex Ly, Donna Ujiiye, Mary C. Clark, PhD, Kathie Viers, RN, Stephen J. Forman, MD, Eileen P. Smith, MD, David S Snyder, MD, Lihua E Budde, MD PhD

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-143412

Published: 2020

Journal Articles

Bridging Radiation Is an Effective Strategy to Control Lymphoma in Preparation for CAR-T: A City of Hope Experience

Savita Dandapani, MD PhD, Geoffrey Shouse, DO, PhD, Jekwon Yeh, MD, Thai Cao, MD, Jeffrey Wong, MD, Lihua E Budde, MD PhD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-143442

Published: 2020

Journal Articles

Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351)

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-140538

Published: 2020

Journal Articles

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

Caron A. Jacobson, MD, Frederick L. Locke, MD, David B. Miklos, MD PhD, Julie M. Vose, MD MBA, Yi Lin, MD PhD, Lihua E Budde, MD PhD, David G. Maloney, MD PhD, Samantha Jaglowski, MD MPH, Peter A. Riedell, MD, Lazaros J. Lekakis, MD, Miguel-Angel Perales, MD, Jenny J. Kim, MD MS, Jun Kawashima, MD, Yin Yang, MS, John M. Rossi, MS, Lovely Goyal, PhD, Sattva S. Neelapu, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136136

Published: 2020

Journal Articles

Results of a Phase 1 Open Label Dose Escalation Trial of AB-205 (Allogeneic Engineered Endothelial Cell Therapy) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT)

Michael Scordo, MD, Lihua E Budde, MD PhD, Mehrdad Abedi, MD, Carolyn Mulroney, MD, Bita Fakhri, MDMPH, Attaphol Pawarode, MDPhD, Bhagirathbhai Dholaria, MBBS, Edward Kavalerchik, MD, Sanjay K. Aggarwal, MD, Muzaffar H. Qazilbash, MD, Paul Finnegan, MD, Sergio A. Giralt, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137257

Published: 2020

Journal Articles

Incidence and Causes of Prolonged Hematologic Toxicity after Chimeric Antigen Receptor T Cell Therapy: A City of Hope (COH) Experience

Geoffrey Shouse, DO, PhD, Thai Cao, MD, Jianying Zhang, Matthew Mei, MD, Alex F. Herrera, MD, Liana Nikolaenko, MD, Jasmine Zain, MD, Tanya Siddiqi, MD, Leslie L. Popplewell, MD FACP, Stephen J. Forman, MD, Lihua E Budde, MD PhD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-143353

Published: 2020

Journal Articles

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Stephen J Schuster, MD, Nancy L Bartlett, MD, Sarit Assouline, MD, Sung-Soo Yoon, MD PhD, Francesc Bosch, MD PhD, Laurie H Sehn, MD, Chan Y. Cheah, Mazyar Shadman, MD MPH, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Matthew Ku, MBBS, FRACP, FRCPA, PhD, Michael C Wei, MD PhD, Shen Yin, PhD, Antonia Kwan, MD PhD MRCPCH, Kasra Yousefi, MSc, Genevive Hernandez, PhD, Chi-Chung Li, PhD, Carol O'Hear, MD PhD, Lihua E Budde, MD PhD

Blood (2019) 134 (Supplement_1): 6.

https://doi.org/10.1182/blood-2019-123742

Published: 2019

Journal Articles

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 1585.

https://doi.org/10.1182/blood-2019-123933

Published: 2019

Journal Articles

Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid Leukemia

Tongyuan Xue, MD, Marissa Del Real, PhD, Emanuela Marcucci, Candida Toribio, Sonia Maryam Setayesh, Stephen J Forman, MD, David A Horne, PhD, Lihua E Budde, MD PhD

Blood (2019) 134 (Supplement_1): 1383.

https://doi.org/10.1182/blood-2019-121486

Published: 2019

Journal Articles

Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Craig A. Portell, MD, Nolan A Wages, PhD, Brad S. Kahl, MD, Lihua E Budde, MD PhD, Robert W. Chen, MD, Jonathon B. Cohen, MDMS, Gina Petroni, PhD, Michael E. Williams, MD

Blood (2019) 134 (Supplement_1): 1535.

https://doi.org/10.1182/blood-2019-128788

Published: 2019

Journal Articles

A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 2834.

https://doi.org/10.1182/blood-2019-123150

Published: 2019

Journal Articles

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

Chi-Chung Li, PhD, Brendan Bender, PhD, Shen Yin, PhD, Zao Li, PhD, Cindy Zhang, MS, Genevive Hernandez, PhD, Antonia Kwan, MD PhD MRCPCH, Laura Sun, PhD, Joanne I Adamkewicz, PhD, Hong Wang, MD PhD DABT, Natalie Dimier, PhD, Sue-Zen Lim, BPharm, Carol O'Hear, MD PhD, Laurie H Sehn, MD, Ian W. Flinn, MD PhD, Sung-Soo Yoon, MD PhD, Lihua E Budde, MD PhD, Chunze Li, PhD, Michael C Wei, MD PhD

Blood (2019) 134 (Supplement_1): 1285.

https://doi.org/10.1182/blood-2019-123961

Published: 2019

Journal Articles

CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma

Tanya Siddiqi, MD, Xiuli Wang, PhD, Joycelynne Palmer, PhD, Leslie L. Popplewell, MD FRCPA, Liana Nikolaenko, MD, Alex F. Herrera, MD, Lihua E Budde, MD PhD, Laura Lim, Vibhuti Vyas, MS, Christine E Brown, PhD, Stephen J. Forman, MD

Blood (2019) 134 (Supplement_1): 4075.

https://doi.org/10.1182/blood-2019-123765

Published: 2019

Journal Articles

Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy

Caron A. Jacobson, MD, Alex F. Herrera, MD, Lihua E Budde, MD PhD, Daniel J. DeAngelo, MD, Christopher Heery, MD, Anthony Stein, MD, Michael D. Jain, MD PhD, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 4107.

https://doi.org/10.1182/blood-2019-128203

Published: 2019

Journal Articles

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

Alex F. Herrera, MD, Jasmine Zain, MD, Kerry J Savage, BSc, MD MSc, Tatyana A. Feldman, MD, Jonathan E Brammer, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Lacolle Peters, Yaira Kurtzman, Stephen J Forman, MD, Steven Rosen, MD, Larry W Kwak, MD PhD, Swaminathan P. Iyer, MD

Blood (2019) 134 (Supplement_1): 4023.

https://doi.org/10.1182/blood-2019-123166

Published: 2019

NARROW

Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma

A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

Durable Leukemia and HIV Remission without Antiviral Therapy Following an Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) Using a Donor with CCR5-Δ32/Δ32 Homozygosity for an Acute Myeloid Leukemia (AML) Patient

Physical Therapy Assessment of Baseline Function and Endurance Predicts Short Term Outcomes in Commercial CAR T Patients with Lymphoma

Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Real World Evaluation of Deviation Outcomes in an Immune Effector Cell Quality Program

Bridging Radiation Is an Effective Strategy to Control Lymphoma in Preparation for CAR-T: A City of Hope Experience

Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351)

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

Results of a Phase 1 Open Label Dose Escalation Trial of AB-205 (Allogeneic Engineered Endothelial Cell Therapy) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT)

Incidence and Causes of Prolonged Hematologic Toxicity after Chimeric Antigen Receptor T Cell Therapy: A City of Hope (COH) Experience

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid Leukemia

Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma

Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only